AstraZeneca spins out a bispecific antibody into a new cancer biotech with partner AbPro
AstraZeneca’s big subsidiary MedImmune and synthetic biology player AbPro are joining forces on a spin-out company which will undertake the development of a preclinical bispecific antibody that targets two key pathways involved in cancer.
The deal builds on MedImmune’s teamwork on first creating the bispecific, which inhibits both Ang2 and VEGF pathways. AbPro will now employ its synthetic biology platform to refine the therapy and take it into the clinic with a spinout company operating under its organization.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.